Inhibition of thrombocyte aggregation as a therapeutic principle;Hemmung der thrombozytenaggregation als therapeutisches prinzip: Ubersicht uber die literatur und derzeit zugelassene thrombozyten- aggregationschemmer

Internist

Volumn 41, Issue SUPPL. 1, 2000, Pages

  Huber, K ^a   Andreesen, R ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; TICLOPIDINE; TIROFIBAN; TRAPIDIL;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG MECHANISM; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT INDICATION;

CLINICAL TRIALS; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM;

EID: 0034012292     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106
2. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308:159-168
3. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminellio C, Augulia F, Pasotti C, Rudelli G (1990) Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The studio della ticlopidina nell'angina instabile group. Circulation 82:17-26
4. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ (1998) A randomized, plazebo-controlled trial of abciximab with primary angioplasty for acute MI. The RAPPORT trial. Circulation 98:734-741
5. Chronos N, Marciniak SJ, Nakada MT (1999) Binding specifity and associated effects of platelet GP IIb/IIIa inhibitors. Eur Heart J Suppl 1 (Suppl E):E11-E17
6. Coller BS (1997) Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 99:1467-1471
7. De Groot PG, Sixma JJ (1998) Glykoproteinrezeptoren der Thrombozytenmembran: Biochemie, Molekularbiologie und Physiologie. In: Müller-Berghaus G, Pötzsch B (eds) Hämostaseologie. Berlin, Springer: 15-25
8. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1999) European Stroke Prevention Study 2. Dipyridamol und Azetylsalizylsäure zur Sekundärprophylaxe des Schlaganfalls. Nervenheilkunde 18:380-390
9. FitzGerald GA (1987) Dipyridamole. N Engl J Med 316:1247-1257
10. Galassi AR, Tamburine C, Nicosia A, Russo G, Grassi R, Monaco A, Giuffrida G (1999) A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheter Cardiovasc Interv 46:162-168
11. Harbrecht U (1998) Die Thrombozytenaggregation: Physiologie und Biochemie. In: Müller-Berghaus G, Pötzsch B (eds) Hämostaseologie. Berlin, Springer: 27-34
12. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients (TASS). N Engl J Med 321:501-507
13. Herbert JM, Frehel D, Vallee E, Kleffer G, Gouy D, Berger Y et al. (1993) Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11:180-198
14. Ito MK, Smith AR, Lee ML (1992) Ticlopidine: a new platelet aggregation inhibitor. Clin Pharm 11:603-617
15. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T et. al. (1990) Prevention of myocardial infarction and stroke in patients with intermittent claudicatio; effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 227:301-308
16. Jordan R, Mascelli MA (1999) Pharmacological differentiation of GP IIb/IIIa inhibitors. Eur Heart J Suppl 1 (Suppl E): E3-E10
17. Lefkovits J, Plow EF, Topol EL (1995) Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332:1553-1559
18. Limet R, David JL, Magotteaux P, Larock MP, Rigo P (1987) Prevention of aortocoronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rate of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 94:87-90
19. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Monici Preti PA, Repetto S, De Servi S, Varani E (1994) Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation 90:2710-2715
20. Mascelli MA, Lance ET, Damarajul L, Wagner CL, Weisman HF, Jordan RE (1998) Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 97:1680-1688
21. Mest HJ (1990) Trapidil: a potent inhibitor of platelet aggregation. J Drug Dev 3:143-149
22. Schömig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the replacement of coronary-artery stents. N Engl J Med 334:1084-1089
23. Schrör K (1992) Acetylsalicylsäure. Stuttgart, Thieme
24. Serruys PW, Darius H, Moris C, O'Neill W, Knudtson M, Anders R, Kleiman JH, Barker K, van Es GA, Symons JO (1999) Long-term oral glycoprotein IIb/IIIa inhibition with xemilofiban in patients undergoing percutaneous coronary intervention: results from EXCITE. Eur Heart J 20 (Abstr Suppl):P2801
25. Sharis PJ, Cannon CP, Loscalzo J (1998) The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 129:394-405
26. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ (1994) Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet Fab 7E3 in high-risk coronary angioplasty. Circulation 90:1757-1764
27. The CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
28. The CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349:1429-1435
29. The CATS Steering Committee (1989) The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 334:1215-1220
30. The CLASSICS Investigators (1999) Clopidogrel plus ASA vs. Ticlopidin plus ASA in stent-patients. Z Kardiol 88 (Suppl 5):1-4
31. The EPIC Investigators (1994) Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961
32. The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med 336:1689-1696
33. The EPISTENT Investigators (1998) Randomised placebo-controlled and ballon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87-92
34. The IMPACT-II Investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPAQ-II. Lancet 349:1422-1428
35. The PRISM Study Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338:1498-1505
36. The PRISM-PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338:1488-1497
37. The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339:436-443
38. The RESTORE Investigators (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453
39. Topol JE, Byzova TV, Plow EF (1999) Platelet GPIIb-IIIa blockers. Lancet 353:227-231
40. Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, Ishikawa K, Masuda Y, Yamaguchi T, Motomiya T, Tamura Y (1999) Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol 83:1308-1313